Immune Checkpoint Inhibition in Breast Cancer

Publication
Article
Special ReportsBreast Cancer (Issue 1)
Volume 1
Issue 1

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.

<<<

Back to the Breast Cancer Special Report

Articles in this issue
Breast Ultrasound Added to Mammography Increases Cancer Detection
Breast Ultrasound Added to Mammography Increases Cancer Detection
Biomarker-Driven Trial of Novel Topo-1 Inhibitor Debuted
Biomarker-Driven Trial of Novel Topo-1 Inhibitor Debuted
Anti-Androgen Not for Male Cancers Alone
Anti-Androgen Not for Male Cancers Alone
Trials Seek Optimal nab-Paclitaxel Regimen for First-Line Use in TNMBC
Trials Seek Optimal nab-Paclitaxel Regimen for First-Line Use in TNMBC
Obesity as a Risk Factor for Inflammatory Breast Cancer
Obesity as a Risk Factor for Inflammatory Breast Cancer
Advances in the Treatment of HER2-Positive Breast Cancer
Advances in the Treatment of HER2-Positive Breast Cancer
Immune Checkpoint Inhibition in Breast Cancer
Immune Checkpoint Inhibition in Breast Cancer

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Jacobson Discusses Second and Third-Line Options for DLBCL

Jacobson Discusses Second and Third-Line Options for DLBCL

Targeted Oncology Staff
April 19th 2025
Article

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Read More

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH
February 6th 2025
Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Voss Examines TKI/IO and IO/IO Regimens in Non–Clear Cell RCC

Voss Examines TKI/IO and IO/IO Regimens in Non–Clear Cell RCC

Targeted Oncology Staff
April 18th 2025
Article

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ipilimumab plus nivolumab in non–clear cell renal cell carcinoma.

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

Hoffmann Examines Data for 17p Deletion in Treatment-Naive CLL

Hoffmann Examines Data for 17p Deletion in Treatment-Naive CLL

Targeted Oncology Staff
April 17th 2025
Article

During a live event, Marc S. Hoffmann, MD, discussed outcomes from the SEQUOIA and ELEVATE-TN studies in chronic lymphocytic leukemia.

Read More

Assessing NCCN Guidelines for Endocrine-Refractory Breast Cancer

Assessing NCCN Guidelines for Endocrine-Refractory Breast Cancer

Targeted Oncology Staff
April 16th 2025
Article

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic breast cancer.

Read More